CB2 Receptor Drugs Behave Very Differently Depending on Which Cellular Pathway Is Measured
A comprehensive screening of CB2 receptor ligands revealed extreme functional selectivity, with some drugs activating one cellular pathway while having no effect on another, complicating the development of CB2-targeted therapeutics.
Quick Facts
What This Study Found
Researchers screened a wide range of CB2 cannabinoid receptor ligands across two signaling pathways: a canonical pathway (inhibition of adenylyl cyclase/G-protein) and a noncanonical pathway (arrestin recruitment).
The results revealed extreme functional selectivity. Classic cannabinoid ligands strongly activated the G-protein pathway but completely failed to recruit arrestins. Most aminoalkylindoles had moderate effects on both pathways. Endocannabinoids were G-protein biased with no arrestin recruitment. One compound (UR144) was arrestin-biased with no significant cyclase inhibition.
Even compounds classified as "antagonists" showed unexpected behavior: AM630 and JTE907 were inverse agonists in the cyclase assay but low-efficacy agonists in the arrestin pathway.
Key Numbers
CP55940 was most potent at both pathways. JWH133 was most efficacious at cyclase. Classic cannabinoids showed zero arrestin recruitment. UR144 was arrestin-biased. Endocannabinoids were G-protein biased.
How They Did This
In vitro pharmacological screening of diverse CB2 receptor ligands in two assay systems: adenylyl cyclase inhibition (G-protein pathway) and beta-arrestin recruitment (noncanonical pathway). Multiple structural classes of compounds were tested.
Why This Research Matters
CB2 receptors are promising therapeutic targets (they mediate anti-inflammatory effects without psychoactive effects), but this study shows that the same drug can behave as an agonist in one pathway and have no effect in another. This means conclusions about CB2 function based on one assay may be misleading.
The Bigger Picture
Functional selectivity (also called biased agonism) is increasingly recognized across many receptor systems, but the degree of bias seen at CB2 is remarkable. This has major implications for cannabinoid drug development, as a drug's therapeutic or adverse effects may depend on which pathway it preferentially activates.
What This Study Doesn't Tell Us
All experiments were in vitro and may not perfectly predict in vivo pharmacology. The study used a single cell expression system, and results may differ in cells with different receptor expression levels or signaling environments. The therapeutic implications of pathway bias at CB2 are still theoretical.
Questions This Raises
- ?Which CB2 signaling pathway mediates the desired anti-inflammatory effects?
- ?Could pathway-biased CB2 agonists improve therapeutic outcomes while reducing side effects?
Trust & Context
- Key Stat:
- Classic cannabinoids strongly activated G-proteins but completely failed to recruit arrestins at CB2
- Evidence Grade:
- This is a comprehensive in vitro pharmacological characterization providing strong evidence for functional selectivity at CB2, with implications for drug development.
- Study Age:
- Published in 2016. The concept of biased agonism has continued to influence cannabinoid drug development strategies.
- Original Title:
- Functional Selectivity of CB2 Cannabinoid Receptor Ligands at a Canonical and Noncanonical Pathway.
- Published In:
- The Journal of pharmacology and experimental therapeutics, 358(2), 342-51 (2016)
- Authors:
- Dhopeshwarkar, Amey(2), Mackie, Ken(22)
- Database ID:
- RTHC-01141
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
What is functional selectivity?
Functional selectivity means that a drug can activate one cellular signaling pathway while having no effect on (or even blocking) another pathway through the same receptor. This study showed that many CB2 ligands are dramatically biased, activating only one of two major downstream pathways.
Why does this matter for medicine?
CB2 receptors are attractive drug targets because they mediate anti-inflammatory effects without causing the psychoactive effects associated with CB1 receptors. But if a drug activates the "wrong" CB2 pathway, it may not produce the desired therapeutic effect. Understanding functional selectivity is essential for developing effective CB2-targeted medicines.
Read More on RethinkTHC
- THC-amygdala-anxiety-brain
- anandamide-weed-withdrawal
- cannabinoid-receptors-recovery-time
- cannabis-developing-brain-teenagers
- cant-enjoy-anything-without-weed
- dopamine-recovery-after-quitting-weed
- endocannabinoid-system-explained-simply
- endocannabinoid-system-withdrawal
- nervous-system-weed-withdrawal-fight-flight
- teen-weed-use-under-18-effects-brain
- thc-brain-withdrawal
- thc-prefrontal-cortex-brain-effects
- weed-cortisol-stress-hormones
- weed-memory-loss-recovery
- weed-motivation-amotivational-syndrome
- weed-nervous-system-effects
- weed-reward-system-brain
Cite This Study
https://rethinkthc.com/research/RTHC-01141APA
Dhopeshwarkar, Amey; Mackie, Ken. (2016). Functional Selectivity of CB2 Cannabinoid Receptor Ligands at a Canonical and Noncanonical Pathway.. The Journal of pharmacology and experimental therapeutics, 358(2), 342-51. https://doi.org/10.1124/jpet.116.232561
MLA
Dhopeshwarkar, Amey, et al. "Functional Selectivity of CB2 Cannabinoid Receptor Ligands at a Canonical and Noncanonical Pathway.." The Journal of pharmacology and experimental therapeutics, 2016. https://doi.org/10.1124/jpet.116.232561
RethinkTHC
RethinkTHC Research Database. "Functional Selectivity of CB2 Cannabinoid Receptor Ligands a..." RTHC-01141. Retrieved from https://rethinkthc.com/research/dhopeshwarkar-2016-functional-selectivity-of-cb2
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.